メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
医学部・消化器内科学・第１
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(16)
研究成果
(313)
フィンガープリント
医学部・消化器内科学・第１が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Endoscopic Ultrasound
96%
Neoplasm
85%
Stomach Cancer
66%
Pancreas Cancer
63%
Narrow Band Imaging
61%
Hepatocellular Carcinoma
54%
Endoscopic Submucosal Dissection
53%
Helicobacter Pylori
50%
Endoscopy
47%
Gastrointestinal Stromal Tumor
45%
Diagnosis
42%
Bevacizumab
40%
Malignant Neoplasm
39%
Atezolizumab
33%
Overall Survival
33%
Endoscopic Ultrasound Guided Fine Needle Biopsy
32%
Echography
31%
Fine-Needle Aspiration
29%
Chronic Pancreatitis
28%
Pancreas Adenocarcinoma
27%
Pylorus
27%
Cancer
26%
Disease
24%
Pancreas Disease
24%
Biliary Tract Drainage
22%
Stenosis
21%
Colorectal Tumor
21%
Pancreas Tumor
20%
Adenoma
20%
Intraductal Papillary Mucinous Tumor
19%
Upper Digestive Tract
19%
Magnifying Endoscopy
18%
Hazard Ratio
18%
Differential Diagnosis
17%
Multivariate Analysis
17%
Biological Marker
17%
Progressive Disease
17%
Liver Function
16%
Scoring System
16%
Ulcerative Colitis
16%
Crohn's Disease
16%
Ras Signaling
16%
White Light Endoscopy
15%
Symptom
14%
Colorectal Cancer
14%
Hematemesis
14%
Confocal Laser Scanning Microscopy
14%
Cholangiocarcinoma
14%
Esophagus
14%
Progression Free Survival
14%
Ulcer
14%
Stomach Mucosa
13%
Diseases
13%
Duodenum
13%
Computer Assisted Tomography
13%
Autoimmune Pancreatitis
13%
Lenvatinib
13%
Choledochoduodenostomy
13%
Immunoglobulin G4
13%
Methylation
13%
Observational Study
13%
microRNA
13%
Helicobacter Infection
13%
Lymphatic Follicle
13%
Macrogol
13%
Adoptive Immunotherapy
13%
Zoledronic Acid
13%
Killer Cell
13%
Jejunum Ulcer
13%
Esophageal Cancer
13%
Polyp
12%
Mucosa
12%
Charlson Comorbidity Index
12%
Survival Rate
11%
Oncology
11%
Eradication Therapy
11%
Arm
11%
Multivariate Logistic Regression Analysis
10%
Chronic Kidney Disease
10%
Psoas Muscle
10%
Morphology
10%
Bleeding
10%
Adverse Event
10%
Predictive Factor
10%
Surgery
9%
CpG Island
9%
Meta-Analysis
9%
Clinical Trial
9%
Pancreatitis
9%
Lymphocyte
9%
Fluorouracil
9%
Clinical Study
9%
Upper Gastrointestinal Bleeding
9%
Diagnostic Accuracy
9%
First-Line Chemotherapy
9%
Steroid Treatment
8%
Cholestasis
8%
Cohort Analysis
8%
Chromoendoscopy
8%
Bile Duct
8%
Pharmacology, Toxicology and Pharmaceutical Science
Stomach Cancer
100%
Liver Cell Carcinoma
91%
Bevacizumab
73%
Chemotherapy
60%
Atezolizumab
59%
Overall Survival
41%
Diseases
35%
Pancreas Cancer
34%
Progression Free Survival
34%
Neoplasm
33%
Adverse Event
31%
Helicobacter Pylori
30%
Malignant Neoplasm
25%
Disease
24%
Clinical Trial
23%
Capecitabine
21%
Sunitinib
19%
Colorectal Tumor
19%
Adenoma
19%
Cisplatin
19%
Lenvatinib
19%
Alpha Fetoprotein
18%
Biological Marker
17%
Colorectal Cancer
16%
Irinotecan
15%
Duodenum Ulcer
15%
Helicobacter Infection
14%
Paclitaxel
14%
Combination Therapy
13%
Atrophic Gastritis
13%
Imatinib
13%
Gastrointestinal Stromal Tumor
13%
Immunotherapy
13%
Observational Study
13%
Ramucirumab
13%
Precancer
13%
microRNA
13%
Zoledronic Acid
13%
Pancreas Islet Cell Tumor
13%
Jejunum Ulcer
13%
Cabozantinib
13%
Comorbidity
13%
Fructan
13%
Placebo
13%
Fluoropyrimidine
12%
Metaplasia
12%
Ulcer
11%
Intestine Flora
11%
Neutropenia
9%
Pancreas Adenocarcinoma
9%
Metastatic Colorectal Cancer
9%
Sorafenib
9%
Fluorouracil
9%
Survival Rate
8%
Solid Malignant Neoplasm
8%
Colorectal Adenoma
8%
Stomach Ulcer
8%
Taxane
8%
Docetaxel
8%
Oxaliplatin
7%
Gamma Urogastrone
7%
Chronic Pancreatitis
7%
Immune Checkpoint Inhibitor
7%
microRNA 31
7%
Bleeding
7%
Inflammatory Bowel Disease
7%
Monotherapy
7%
Crohn's Disease
7%
Trastuzumab
7%
End Stage Liver Disease
7%
Polyp
7%
Prevalence
6%
Intestine Metaplasia
6%
Sclerosing Cholangitis
6%
Omeprazole
6%
Immunoglobulin G4
6%
Small Interfering RNA
6%
Regorafenib
6%
Colon Polyposis
6%
Liver Metastasis
6%
Vascular Disease
6%
Oncolytic Herpes Virus
6%
Xenobiotic Agent
6%
Cetuximab
6%
Anticoagulation Therapy
6%
Gastrointestinal Hemorrhage
6%
Neuroendocrine Tumor
6%
Tumor Necrosis Factor
6%
Heat Shock Protein 70
6%
Hypovitaminosis D
6%
UFT
6%
Intestine Tumor
6%
Liver Disease
6%
Remission
6%
Diabetes Mellitus
6%
Second-Line Chemotherapy
6%
Hepatitis B Virus
6%
Chronic Hepatitis B
6%
Adjuvant
6%
microRNA 124
6%
Keyphrases
Atezolizumab Plus Bevacizumab
32%
Advanced Hepatocellular Carcinoma
27%
Gastrointestinal Stromal Tumor
24%
Gastric Cancer
21%
Advanced Gastric Cancer
20%
Pre-microRNA
19%
Lenvatinib
18%
Chemotherapy
16%
Endoscopic Ultrasound-guided
15%
Steroid Treatment
14%
Clinical Outcomes
14%
Endoscopic Ultrasound
14%
Hepatocellular Carcinoma
13%
Endoscopic Ultrasonography
13%
Ulcerative Colitis
13%
Pancreatic Neuroendocrine Tumors (pNETs)
13%
REG4
13%
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD)
13%
Endoscopic Ultrasound-guided Choledochoduodenostomy
13%
Common Genetic Variants
13%
IgG4-related Sclerosing Cholangitis
13%
Gastrointestinal Subepithelial Lesions
13%
Combination Therapy
13%
N-score
13%
Helicobacter Pylori Eradication
13%
Endoscopic Features
13%
Rs3746444
13%
Atezolizumab
12%
Overall Survival
11%
Gastric Cancer Patients
11%
Adverse Events
10%
Rs11614913
10%
Liver Function
10%
Docetaxel
9%
MiR-146a rs2910164
9%
Cancer Risk
9%
Magnifying Endoscopy with Narrow-band Imaging
9%
Differential Diagnosis
9%
Tumor
8%
Abdominal Ultrasonography
8%
Preoperative Diagnosis
8%
Depressed Lesion
7%
Disease Control Rate
7%
Odds Ratio
7%
Multivariate Analysis
7%
Chromoendoscopy
7%
Clinical Practice
7%
Progression-free Survival
7%
Pancreatic Cancer
7%
Pancreatic Diseases
7%
Complete Response
7%
Gene Polymorphism
7%
IgG4-positive
7%
White Light Endoscopy
7%
Single nucleotide Polymorphism
6%
Periampullary Cancer
6%
Biliary Tract Carcinoma
6%
Interleukin-17 (IL-17)
6%
Solid Pseudopapillary Tumor
6%
Ramucirumab
6%
Abdominal Lymphadenopathy
6%
Gastrointestinal Submucosal Tumor
6%
Second-look Endoscopy
6%
Transabdominal
6%
Two-step Method
6%
Confocal Laser Endomicroscopy
6%
Peutz-Jeghers Polyp
6%
Survey in Japan
6%
Nationwide Survey
6%
CapeOX
6%
New FP
6%
Cape
6%
Ulcerative Colitis-associated Neoplasia
6%
Endoscopic Staging
6%
Leukocyte DNA
6%
IGF2 DMR
6%
Protease-activated Receptor 2 (PAR2)
6%
STI571
6%
Imatinib Failure
6%
Food Taste
6%
Diagnostic Biomarker
6%
Individual Response
6%
Response to Food
6%
Metastatic Pancreatic Cancer
6%
Palliative Biliary Drainage
6%
EUS-guided Choledochoduodenostomy
6%
Endoscopic Pancreatic Stent
6%
Feasibility Trial
6%
Anti-oncomir
6%
Gene Aberrations
6%
Plummer-Vinson Syndrome
6%
Esophageal Web
6%
Iron Therapy
6%
MIF Gene
6%
Pancreatology
6%
IL-1 Polymorphism
6%
International Association
6%
TNF Polymorphism
6%
Performance Status 2
6%
Stomach Cancer
6%